| scholarly article | Q13442814 |
| P50 | author | Renate Kirschner-Schwabe | Q56956526 |
| Arend von Stackelberg | Q71500028 | ||
| Stefanie Groeneveld-Krentz | Q71501620 | ||
| P2093 | author name string | Jana Hof | |
| Christian Hagemeier | |||
| Karl Seeger | |||
| Cornelia Eckert | |||
| Günter Henze | |||
| Wolf-Dieter Ludwig | |||
| Leonid Karawajew | |||
| Shabnam Shalapour | |||
| Peter Rhein | |||
| Gabriele Körner | |||
| Claudia van Schewick | |||
| P2860 | cites work | Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database | Q29616468 |
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lymphoblastic leukemia | Q18553852 |
| leukemia | Q29496 | ||
| P304 | page(s) | 3185-93 | |
| P577 | publication date | 2011-08-10 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia | |
| P478 | volume | 29 |
| Q64053615 | 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies |
| Q30008897 | A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia |
| Q42360020 | A p53-regulated apoptotic gene signature predicts treatment response and outcome in pediatric acute lymphoblastic leukemia |
| Q38734441 | A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program. |
| Q52751888 | A rhabdomyosarcoma patient from a Li-Fraumeni syndrome family: a case report and literature review |
| Q27852067 | Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. |
| Q24602387 | Acute lymphoblastic leukaemia |
| Q92947561 | Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia |
| Q42371687 | B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy |
| Q42021950 | Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia |
| Q27612411 | CIViC database |
| Q52793910 | Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology |
| Q53814000 | Childhood relapsed acute lymphoblastic leukemia: Biology and recent treatment progress |
| Q37426281 | Coexistence of iAMP21 and ETV6-RUNX1 fusion in an adolescent with B cell acute lymphoblastic leukemia: literature review of six additional cases |
| Q36106034 | Comparative genomics reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic leukemia |
| Q27853385 | Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia |
| Q48323019 | Copy number profiling of adult relapsed B-cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms |
| Q27025242 | Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q38005040 | Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments |
| Q26824387 | Diagnosis and subclassification of acute lymphoblastic leukemia |
| Q33886848 | Does TP53 guard ALL genomes? |
| Q89497272 | Drug Resistance Biomarkers and Their Clinical Applications in Childhood Acute Lymphoblastic Leukemia |
| Q43509391 | Effect of TP53 codon 72 and MDM2 SNP309 polymorphisms on survival of gastric cancer among patients who receiving 5-fluorouracil-based postoperative adjuvant chemotherapy |
| Q35178411 | Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia |
| Q55216431 | Effects of CB2 and TRPV1 receptors' stimulation in pediatric acute T-lymphoblastic leukemia. |
| Q95846602 | Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features |
| Q38999126 | Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. |
| Q94452289 | Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children |
| Q64102183 | Functional Diversity of p53 in Human and Wild Animals |
| Q35922398 | Genome-Wide DNA Copy Number Analysis of Acute Lymphoblastic Leukemia Identifies New Genetic Markers Associated with Clinical Outcome |
| Q61570969 | Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in wild-type Ewing sarcoma |
| Q38223490 | Genomic characterization of acute leukemias |
| Q38381463 | Genomics in acute lymphoblastic leukaemia: insights and treatment implications |
| Q39027780 | Germ line mutations associated with leukemias |
| Q38723094 | Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia |
| Q38762129 | Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia |
| Q38837564 | Identifying novel therapeutic agents using xenograft models of pediatric cancer |
| Q36392660 | Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program |
| Q37262456 | Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia |
| Q28274115 | LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors |
| Q41156034 | Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience |
| Q36253975 | MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia |
| Q92265010 | Mechanisms of NT5C2-Mediated Thiopurine Resistance in Acute Lymphoblastic Leukemia |
| Q36290242 | Molecular genetics of B-precursor acute lymphoblastic leukemia |
| Q39399293 | Mutational analysis of TP53 gene in Tunisian familial hematological malignancies and sporadic acute leukemia cases |
| Q50614792 | Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia. |
| Q42348458 | NOTCH1 mutation, TP53 alteration and myeloid antigen expression predict outcome heterogeneity in children with first relapse of T-cell acute lymphoblastic leukemia |
| Q52593673 | New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update. |
| Q41573471 | Novel BCR-ABL1 fusion and leukemic mutations of SETBP1, PAX5, and TP53 detected by next generation sequencing in chronic myeloid leukemia |
| Q26829775 | Novel agents and biomarkers for acute lymphoid leukemia |
| Q64096257 | Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial |
| Q28078609 | P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia |
| Q36163029 | Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? |
| Q36983745 | Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia |
| Q27851831 | Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia |
| Q34580110 | Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition |
| Q26864460 | Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine |
| Q50905546 | Regulation of p53 and survivin by prodigiosin compound derived from Serratia marcescens contribute to caspase-3-dependent apoptosis in acute lymphoblastic leukemia cells |
| Q61953181 | Relapsed Acute Lymphoblastic Leukemia of Childhood |
| Q38103645 | Relapsed childhood acute lymphoblastic leukaemia |
| Q35744654 | Somatic drivers of B-ALL in a model of ETV6-RUNX1; Pax5(+/-) leukemia |
| Q37452977 | Somatic inactivation of Tp53 in hematopoietic stem cells or thymocytes predisposes mice to thymic lymphomas with clonal translocations |
| Q36619115 | Stromal cell-mediated mitochondrial redox adaptation regulates drug resistance in childhood acute lymphoblastic leukemia |
| Q52885084 | Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB |
| Q39047607 | TP53 Mutations in Hypodiploid Acute Lymphoblastic Leukemia |
| Q50906605 | TP53 in adult acute lymphoblastic leukemia |
| Q38177771 | TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia |
| Q46317683 | TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens |
| Q43181359 | TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy |
| Q91753706 | TP53, ETV6 and RUNX1 germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia |
| Q38793389 | Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients |
| Q37995811 | The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia |
| Q55457316 | The clinicopathological and prognostic significance of TP53 alteration in K27M mutated gliomas: an individual-participant data meta-analysis. |
| Q38965030 | The dual-acting chemotherapeutic agent Alchemix induces cell death independently of ATM and p53. |
| Q37574743 | The genomic landscape of hypodiploid acute lymphoblastic leukemia |
| Q48090552 | The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL. |
| Q40562742 | The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases |
| Q34100901 | The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells |
| Q91898958 | Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia |
| Q92365312 | Therapeutic targeting of mutated p53 in acute lymphoblastic leukemia |
| Q38633437 | Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia |
| Q52887374 | Treatment of children and adolescents with relapsed ALL: therapy target long-term healing |
| Q35196702 | Treatment of pediatric acute lymphoblastic leukemia |
| Q89770383 | Upfront Treatment Influences the Composition of Genetic Alterations in Relapsed Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia |
| Q47369729 | WT1 loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia |
| Q89454887 | [Rita induce acute lymphoblostic leukemia cell apoptosis by activating P53 pathway] |
| Q64897707 | cAMP-mediated autophagy inhibits DNA damage-induced death of leukemia cells independent of p53. |
Search more.